ClinicalTrials.gg
RecruitingNCT05491304Updated Oct 6, 2022

Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis

A Phase 4 interventional study of Dexamethasone and Etoposide in Hemophagocytic Lymphohistiocytoses and Cytokine Storm, sponsored by The Children's Hospital of Zhejiang University School of Medicine. Recruiting at 1 site in China. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2022-10-06.

Sponsored by The Children's Hospital of Zhejiang University School of Medicine · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
1 Day to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies testing etoposide in Lymphohistiocytosis, Hemophagocytic — 3 open to participants now, 3 under way, 1 of them phase 3. Etoposide · Lymphohistiocytosis, Hemophagocytic.

Planned enrollment
Largest of 13
400 · median 31
Started
2022
with 1 other
Phase 4
2 of 13
1 open now
Registered
11th of 13
by date
Lead sponsor
1 of 13
The Children's Hospital of Zhejiang University School of Medicine

Among the 13 studies testing etoposide in Lymphohistiocytosis, Hemophagocytic, this one has the largest planned enrollment, is one of 2 that started in 2022, is one of 2 in phase 4, and was the 11th registered.

Lymphohistiocytosis, Hemophagocytic

111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.

Browse Lymphohistiocytosis, Hemophagocytic studies →

Open to participants now

3 of the 13 studies testing etoposide in Lymphohistiocytosis, Hemophagocytic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About etoposide

Etoposide: first FDA approval 1983 (VEPESID). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 1 Day to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing etoposide in Lymphohistiocytosis, Hemophagocytic, or all of them as a file.
02

Study summary

Hemophagocytic lymphohistiocytosis (HLH) is a rapidly fatal disease caused by immune-dysregulation characterized by hypercytokinemia, with about 30%-40% of patients suffering death in children. Stratification strategy and individualized treatment is important to improve the survival. In our recent retrospective study, risk stratification based on IL-10 and IFN-γ levels well distinguished patients with different outcomes. In this multicenter prospective study, we will enroll the newly diagnosed pediatric HLH patients and divide them into low, intermediate and high-risk cytokine groups according to IFN-γ and IL-10 levels. The patients'clinical manifestation and laboratory findings will be further evaluated into severe and non-severe groups. For low/intermediate risk and non-severe patients, steroid or ruxolitinib will be used initially; while those with high risk or severe diseases, DXM+VP16±ruxolitinib will be administered. The treatment strategy could be adjusted after evaluation 48-72 hours later.

Read the detailed description

Background and objectives: Hemophagocytic lymphohistiocytosis (HLH) is a rapidly fatal disease caused by immune-dysregulation characterized by hypercytokinemia, with about 30%-40% of patients suffering death in children. Early death is an important issue in HLH treatment, which is greatly caused by hypercytokinemia resulting in multi-organ disfunction and partially due to the treatment toxicities. Thus, stratification strategy and individualized treatment is important to improve the survival. In our recent retrospective study which enrolled 256 pediatric patients, the patients were stratified into low, intermediate and high risk according to their IL-10 and IFN-γ levels. The 8-week mortality for low, intermediate and high-risk patients were 5.4±2.4%, 16.9±3.4% and 48.7±8.0%, and the 5-year OS rate were 82.9±40%, 67.0±4.3% and 51.3±8.0%, respectively. This indicated that IFN-γ and IL-10 are helpful for stratifying HLH patients into different risk groups to receive individualized therapies. However, evidence of cytokine application based on multi-center prospective study is still lacking. The aim of this protocol is to establish a model to early identify the patients with low and high mortality and to guide the precise treatment of pediatric HLH.

Methods and protocol design: A multicenter prospective study in Asian countries is to be launched for children with HLH. The inclusion criterion is newly diagnosed pediatric HLH patients who has not received steroids or etoposide when enrollment. In this study, the patients are identified as low, intermediate and high-risk cytokine groups according to their cytokine levels: (1) low-risk: IFN-γ\<3700pg/mL and IL-10\<200pg/mL; (2) intermediate-risk: IFN-γ\<3700pg/mL and IL-10≥200pg/mL; (3) high-risk: IFN-γ≥3700pg/mL. The patients' clinical manifestation and laboratory findings were evaluated as well and those fulfill either one of the following criteria were considered as "severe": (1) present ≥2 out of 3 ⅰ, albumin\<26.0 g/L; ⅱ, direct bilirubin>55.0μmol/L; ⅲ, fibrinogen\<0.75g/L. (2) CNS involvement, shock, mechanical ventilation, renal failure.

Based on the cytokine risk and disease severity, different intensity of treatment will be started. For low/intermediate risk and not severe patients, steroid or ruxolitinib will be used initially; while those with high risk or "severe" disease, DXM+VP16±ruxolitinib will be administered. The treatment strategy could be adjusted after evaluation 48-72 hours later based on treatment respose and cytokine levels. A total of 400 pediatric patients under 18 years old are to be recruited. The primary end-point of the study is the 8-week responsive rates and mortality, and one-year overall survival.

03

Conditions studied

  • Hemophagocytic Lymphohistiocytoses
  • Cytokine Storm

Keywords

  • Hemophagocytic Lymphohistiocytoses
  • Cytokine Storm
  • Ruxolitinib
  • Interferon-gamma
  • Interleukin-10
  • Child
  • Stratification therapy
04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from one day to 18 years old;
  • Newly diagnosed HLH, fulfilling the HLH criteria;
  • To observed the early diagnosis role of cytokines, patients who is suspected to be HLH and fulfill 3 out of 8 criteria can be pre-enrolled.

Exclusion criteria

Exclusion Criteria:

  • treated with or etoposide within 72 hours before diagnosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Non-severe DXM group

    Dexamethasone (DXM): week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.

    Drug: Dexamethasone

  • Experimental
    Non-severe Ruxo group

    Ruxolitinib(Ruxo): body weight (BW)\<10kg: 2.5mg Bid; 10-20kg: 5mg Bid; \>20kg: 10mg Bid; Orally for 4 weeks.

    Drug: Ruxolitinib

  • Experimental
    Severe HLH-94 group

    DXM: week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering. Etoposide (VP16): 100-150mg/m2 twice in the first two weeks, and once every week to week 8.

    Drug: Dexamethasone · Drug: Etoposide

  • Experimental
    Severe HLH-94 plus ruxolitinib group

    DXM: week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering. Etoposide (VP16): 100-150mg/m2 twice in the first two weeks, and once every week to week 8. Ruxolitinib(Ruxo): body weight (BW)\<10kg: 2.5mg Bid; 10-20kg: 5mg Bid; \>20kg: 10mg Bid; Orally for 4 weeks.

    Drug: Dexamethasone · Drug: Etoposide · Drug: Ruxolitinib

Interventions

  • Single drug in non-severe group; combined with etoposide±ruxolitinib in severe group.

    Also known as: Steroid, Corticosteroid

  • Used in severe group combined with etoposide.

    Also known as: VP16

  • Single drug in non-severe group; combined with etoposide and dexamethasone in severe group.

    Also known as: JAK1/2 inhibitor

06

What researchers measure

Primary outcomes

  1. Complete remission (CR)

    Complete remission rate in 8th week

    Time frame: 8th week after the initial of therapy

  2. Overall survival (OS)

    Overall survival rate in one year

    Time frame: One year after enrollment

  3. overall response rate (ORR)

    including the proportion of patients achieving CR, PR and HLH improvement

    Time frame: At the 4th and 8th week of treatment

  4. Mortality

    8-week mortality

    Time frame: At the 8th week of diagnosis

Secondary outcomes

  1. Reactivation rate

    The relapse rate of disease

    Time frame: Any time during the first year after diagnosis

  2. Partial remission (PR)

    Partial remission rate in 4th week

    Time frame: 4th week after the initial of therapy

  3. Rate of Early Death

    Death occurred within 2 weeks after diagnosis

    Time frame: 2nd week after diagnosis

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bergsten E, Horne A, Arico M, Astigarraga I, Egeler RM, Filipovich AH, Ishii E, Janka G, Ladisch S, Lehmberg K, McClain KL, Minkov M, Montgomery S, Nanduri V, Rosso D, Henter JI. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017 Dec 21;130(25):2728-2738. doi: 10.1182/blood-2017-06-788349. Epub 2017 Sep 21. PubMed 28935695 ↗
  • Xu XJ, Tang YM. Dilemmas in diagnosis and management of hemophagocytic lymphohistiocytosis in children. World J Pediatr. 2020 Aug;16(4):333-340. doi: 10.1007/s12519-019-00299-3. Epub 2019 Sep 10. PubMed 31506890 ↗
  • Tang Y, Xu X, Song H, Yang S, Shi S, Wei J, Pan B, Zhao F, Liao C, Luo C. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol. 2008 Oct;143(1):84-91. doi: 10.1111/j.1365-2141.2008.07298.x. Epub 2008 Jul 31. PubMed 18673367 ↗
  • Xu XJ, Tang YM, Song H, Yang SL, Xu WQ, Zhao N, Shi SW, Shen HP, Mao JQ, Zhang LY, Pan BH. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012 Jun;160(6):984-90.e1. doi: 10.1016/j.jpeds.2011.11.046. Epub 2012 Jan 9. PubMed 22226576 ↗
  • Xu XJ, Luo ZB, Song H, Xu WQ, Henter JI, Zhao N, Wu MH, Tang YM. Simple Evaluation of Clinical Situation and Subtypes of Pediatric Hemophagocytic Lymphohistiocytosis by Cytokine Patterns. Front Immunol. 2022 Feb 28;13:850443. doi: 10.3389/fimmu.2022.850443. eCollection 2022. PubMed 35296096 ↗
  • Wang J, Zhang R, Wu X, Li F, Yang H, Liu L, Guo H, Zhang X, Mai H, Li H, Wang Z. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial. Br J Haematol. 2021 May;193(4):761-768. doi: 10.1111/bjh.17331. Epub 2021 Feb 9. PubMed 33559893 ↗
  • Zhang Q, Zhao YZ, Ma HH, Wang D, Cui L, Li WJ, Wei A, Wang CJ, Wang TY, Li ZG, Zhang R. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis. Blood. 2022 Jun 16;139(24):3493-3504. doi: 10.1182/blood.2021014860. PubMed 35344583 ↗
  • Ehl S, Astigarraga I, von Bahr Greenwood T, Hines M, Horne A, Ishii E, Janka G, Jordan MB, La Rosee P, Lehmberg K, Machowicz R, Nichols KE, Sieni E, Wang Z, Henter JI. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1508-1517. doi: 10.1016/j.jaip.2018.05.031. Epub 2018 Jul 4. PubMed 30201097 ↗
  • Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31. doi: 10.1002/pbc.21039. PubMed 16937360 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Dec 2024, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2022
First posted
Aug 8, 2022
StartActual
Sep 1, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2025
Last update
Oct 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05491304
Lead sponsor
The Children's Hospital of Zhejiang University School of Medicine
Collaborators
The Second Hospital of Anhui Medical University, Union hospital of Fujian Medical University, Children's Hospital of Fudan University, Zunyi Medical College, Hunan Provincial People's Hospital, Tongji Hospital, Children's Hospital of Nanjing Medical University, The Affiliated Hospital of Qingdao University, Qilu Hospital of Shandong University, Shanghai Children's Medical Center, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Children's Hospital, Shenzhen Children's Hospital, West China Second University Hospital, Children's Hospital of Soochow University, Second Affiliated Hospital of Wenzhou Medical University, Wuhan Children's Hospital, Institute of Hematology & Blood Diseases Hospital, China, The Third Xiangya Hospital of Central South University, First Affiliated Hospital, Sun Yat-Sen University
Responsible party
Xiaojun Xu (chief physician, The Children's Hospital of Zhejiang University School of Medicine) — Principal investigator
First posted
Aug 8, 2022
Start date
Sep 1, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Oct 6, 2022

Study contacts

Xiaojun Xu, MD
Contact
xuxiaojun@zju.edu.cn
+8657188873617
Zebin Luo, MD
Contact
645747676@qq.com
+8618758196529
Xiaojun Xu, MD
principal investigator · The Children's Hospital of Zhejiang University School of Medicine
Yongmin Tang, MD
principal investigator · The Children's Hospital of Zhejiang University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone · Etoposide · Ruxolitinib

Start the discussion